Literature DB >> 16878974

Computational solvent mapping reveals the importance of local conformational changes for broad substrate specificity in mammalian cytochromes P450.

Karl H Clodfelter1, David J Waxman, Sandor Vajda.   

Abstract

Computational solvent mapping moves small organic molecules as probes around a protein surface, finds favorable binding positions, clusters the conformations, and ranks the clusters on the basis of their average free energy. Prior mapping studies of enzymes, crystallized in either substrate-free or substrate-bound form, have shown that the largest number of solvent probe clusters invariably overlaps in the active site. We have applied this method to five cytochromes P450. As expected, the mapping of two bacterial P450s, P450 cam (CYP101) and P450 BM-3 (CYP102), identified the substrate-binding sites in both ligand-bound and ligand-free P450 structures. However, the mapping finds the active site only in the ligand-bound structures of the three mammalian P450s, 2C5, 2C9, and 2B4. Thus, despite the large cavities seen in the unbound structures of these enzymes, the features required for binding small molecules are formed only in the process of substrate binding. The ability of adjusting their binding sites to substrates that differ in size, shape, and polarity is likely to be responsible for the broad substrate specificity of these mammalian P450s. Similar behavior was seen at "hot spots" of protein-protein interfaces that can also bind small molecules in grooves created by induced fit. In addition, the binding of S-warfarin to P450 2C9 creates a high-affinity site for a second ligand, which may help to explain the prevalence of drug-drug interactions involving this and other mammalian P450s.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16878974     DOI: 10.1021/bi060343v

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.

Authors:  Drew R Jones; So-Young Kim; Michael Guderyon; Chul-Ho Yun; Jeffery H Moran; Grover P Miller
Journal:  Chem Res Toxicol       Date:  2010-05-17       Impact factor: 3.739

2.  Combination of docking, molecular dynamics and quantum mechanical calculations for metabolism prediction of 3,4-methylenedioxybenzoyl-2-thienylhydrazone.

Authors:  Rodolpho C Braga; Vinícius M Alves; Carlos A M Fraga; Eliezer J Barreiro; Valéria de Oliveira; Carolina H Andrade
Journal:  J Mol Model       Date:  2011-09-08       Impact factor: 1.810

3.  Effective virtual screening protocol for CYP2C9 ligands using a screening site constructed from flurbiprofen and S-warfarin pockets.

Authors:  Tímea Polgár; Dóra K Menyhárd; György M Keseru
Journal:  J Comput Aided Mol Des       Date:  2007-10-25       Impact factor: 3.686

4.  The structural basis of pregnane X receptor binding promiscuity.

Authors:  Chi-Ho Ngan; Dmitri Beglov; Aleksandra N Rudnitskaya; Dima Kozakov; David J Waxman; Sandor Vajda
Journal:  Biochemistry       Date:  2009-12-08       Impact factor: 3.162

5.  Conformational dynamics in the F/G segment of CYP51 from Mycobacterium tuberculosis monitored by FRET.

Authors:  Galina I Lepesheva; Matej Seliskar; Charles G Knutson; Nina V Stourman; Damjana Rozman; Michael R Waterman
Journal:  Arch Biochem Biophys       Date:  2007-06-06       Impact factor: 4.013

Review 6.  Biochemical functional predictions for protein structures of unknown or uncertain function.

Authors:  Caitlyn L Mills; Penny J Beuning; Mary Jo Ondrechen
Journal:  Comput Struct Biotechnol J       Date:  2015-02-18       Impact factor: 7.271

7.  Druggable protein interaction sites are more predisposed to surface pocket formation than the rest of the protein surface.

Authors:  David K Johnson; John Karanicolas
Journal:  PLoS Comput Biol       Date:  2013-03-07       Impact factor: 4.475

8.  Selective prediction of interaction sites in protein structures with THEMATICS.

Authors:  Ying Wei; Jaeju Ko; Leonel F Murga; Mary Jo Ondrechen
Journal:  BMC Bioinformatics       Date:  2007-04-09       Impact factor: 3.169

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.